Highlights of This Issue 4491

SPECIAL FEATURES

Volumes to Learn: Advancing Therapeutics with Innovative Computed Tomography Image Data Analysis
Michael L. Maitland
See article p. 4647

X-linked Inhibitor of Apoptosis: A Chemoresistance Factor or a Hollow Promise
Hamid Kashkar

Targeting Cell Division Cycle 7 Kinase: A New Approach for Cancer Therapy
Alessia Montagnoli, Jürgen Moll, and Francesco Colotta

DNA Repair: A Reinvigorated Therapeutic Target
Susan E. Bates

DNA Damage and Repair in Translational Oncology: An Overview
Eddie Reed

Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer
Christina M. Annunziata and Joyce O'Shaughnessy

Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target
Ruth Plummer

Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
Christophe E. Redon, Asako J. Nakamura, Yong-Wei Zhang, Jiuping (Jay) Ji, William M. Bonner, Robert J. Kinders, Ralph E. Parchment, James H. Doroshow, and Yves Pommier

Epigenetic Modifications in Double-Strand Break DNA Damage Signaling and Repair
Dorine Rossetto, Andrew W. Truman, Stephen J. Kron, and Jacques Côté

"Contextual" Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA Repair
Norman Chan and Robert G. Bristow

Molecular Pathways

Regulation of Excision Repair Cross-Complementation Group 1 by Snail Contributes to Cisplatin Resistance in Head and Neck Cancer

System-Level Analysis of Neuroblastoma Tumor-Initiating Cells Implicates AURKB as a Novel Drug Target for Neuroblastoma
Olena Morozova, Milijana Vojvodic, Natalie Grinshtein, Loen M. Hansford, Kim M. Blakely, Alexandra Maslova, Martin Hirst, Timothee Cezard, Ryan D. Morin, Richard Moore, Kristen M. Smith, Freda Miller, Paul Taylor, Nina Thiessen, Richard Varhol, Yongqiu Zhao, Steven Jones, Jason Moffat, Thomas Kislinger, Michael F. Moran, David R. Kaplan, and Marco A. Marra

CANCER THERAPY: PRECLINICAL

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
Krithika N. Kodumudi, Karrune Woan, Danielle L. Gilvary, Eva Sahakian, Sheng Wei, and Julie Y. Djeu

Inhibitory Effect of Silibinin against Azoxy methane-Induced Colon Tumorigenesis in A/J Mice
Kameswaram Ravichandran, Balaiya Velmurugan, Mallikarjuna Gu, Rana P. Singh, and Rajesh Agarwal
Molecular Analysis of Non–Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition


An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors


Expression of Receptors for Luteinizing Hormone-Releasing Hormone (LH-RH) in Prostate Cancers following Therapy with LH-RH Agonists

Stephen V. Liu, Andrew V. Schally, Debra Hawes, Shigang Xiong, Laden Fazli, Martin Gleave, Jie Cai, Susan Groshen, Frank Brands, Juergen Engel, and Jacek Pinski

Correction: A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed against EGFR in Patients with Advanced Solid Malignancies

Correction: A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed against EGFR in Patients with Advanced Solid Malignancies

Makoto Nagahara, Koshi Mimori, Akemi Kataoka, Hideshi Ishii, Fumiaki Tanaka, Tsuyoshi Nakagawa, Takeharu Sato, Shinji Ono, Kenichi Sugihara, and Masaki Mori

Jumonji Domain Containing 1A Is a Novel Prognostic Marker for Colorectal Cancer: In vivo Identification from Hypoxic Tumor Cells

Mamoru Uemura, Hirofumi Yamamoto, Ichiro Takegawa, Koshi Mimori, Hideyuki Hemmi, Tsuneaki Mizushima, Masataka Ikeda, Mitsugu Sekimoto, Nariaki Matsumura, Yuichihiro Doki, and Masaki Mori

A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development

Binsheng Zhao, Geoffrey R. Oxnard, Chaya S. Moskowitz, Mark G. Kris, William Pao, Pingzhen Guo, Valerie M. Rusch, Marc Ladanyi, Naiyer A. Rizvi, and Lawrence H. Schwartz

See commentary p. 4493
ABOUT THE COVER

Clinical Use of γH2AX and PAR: Image of an anagen hair bulb plucked from the scalp of a cancer patient 24 hours after drug infusion. γH2AX antibody reveals DNA double-strand breaks (green foci) in cell nuclei (red). Imaged using a Nikon PCM 2000 laser scanning confocal microscope. For details, please see the article by Redon and colleagues on p. 4532 of this issue.
Clinical Cancer Research

16 (18)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/16/18

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.